AstraZeneca and MSD's PARP inhibitor Lynparza has improved long-term survival when given as adjuvant therapy for early breast cancer – the first drug in the class to show that in a clinical trial.

AstraZeneca and Merck & Co’s partnership to develop ovarian cancer drug Lynparza has got off to a good start after the FDA approved its use in a wider group of women. The drug has been approved ...

An icon of a desk calendar. An icon of a circle with a diagonal line across. An icon of a block arrow pointing to the right. An icon of a paper envelope. An icon of the Facebook "f" mark.

Unite.AI is committed to rigorous editorial standards. We may receive compensation when you click on links to products we review. Please view our affiliate disclosure. Creating a strong brand identity ...